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Abstract
The treatment of depression during pregnancy is both a common and complex clinical challenge.
The decision to expose the fetus to antidepressant medication during pregnancy must be weighed
against the risks of untreated maternal depression to both mother and fetus. Maternal depression
during pregnancy has been associated with increased rates of preterm birth and maternal substance
use. The safety of antidepressant use during pregnancy appears to be largely reassuring but there
remain two areas of controversy including neonatal withdrawal syndrome and primary pulmonary
hypertension of the newborn (PPHN). Individualized treatment recommendations based on the
patient's history are essential in order to optimize outcomes.
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Introduction
Prescription drug use during pregnancy is a common phenomenon. Between 1996 and 2000,
64% of all women who delivered a child had a drug other than a vitamin or mineral supplement
prescribed in the 270 days before delivery, 97% of which were not FDA Pregnancy Category
A (see Table 1) (1). The choice of whether to prescribe a medication during pregnancy is a
difficult one and prescribing must take into account the potential risks and benefits to the unborn
infant and the mother. When the mother is diagnosed with a potentially life threatening illness,
the choice of whether to prescribe a medication often becomes obvious. However, when the
mother faces a illness that is not viewed as immediately life threatening, the decision to
prescribe becomes more complicated. One area of controversy is the use of antidepressants
during pregnancy.
There are a number of reasons why the use of antidepressants during pregnancy is controversial.
Firstly, antidepressants are often considered “luxury” medications- i.e. ones that can and should
be stopped during pregnancy, in the same category as ibuprofen or sleep aids. This belief stems
from common misperceptions of Major Depression (MDD) and other psychiatric illnesses as
different from, and not as serious as, medical illnesses. Secondly, antidepressants are often
prescribed in patients that do not meet full diagnostic criteria for MDD or other psychiatric
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illness. For example, as with any medical illness, it may be appropriate to discontinue
antidepressant medications during pregnancy in patients whose symptoms were subsyndromal,
i.e. mild or transient,. Thirdly, discontinuation of antidepressants during pregnancy has risks.
The psychiatric literature has demonstrated that exposure to untreated MDD during pregnancy
can have serious adverse consequences for the developing neonate such as premature birth,
low birth weight and future behavioral disturbances (Li et al 2009, Davis et al 2005). Lastly,
a majority of women will relapse with MDD if their antidepressants are stopped during
pregnancy significantly increasing the risk of postpartum depression (PPD) (2;3). .
This review will provide guidance regarding the complex decision making process and other
issues surrounding antidepressant use during pregnancy and lactation. Common questions that
arise in clinical practice will be discussed including: Which antidepressants are safer during
pregnancy? What are the FDA recommendations? Should the antidepressant be tapered prior
to labor and delivery? What about withdrawal symptoms or adverse outcomes for the infant?
Why use antidepressants during pregnancy?
The treatment of women with depression or other psychiatric illness during the perinatal period
(pregnancy or postpartum) poses a complex clinical challenge. However, given that perinatal
depression has an estimated prevalence rate of at least 10% in the general population, this
challenge is routinely encountered and must be squarely addressed in order to help the patient
make an informed decision (4-7). Rates of antidepressant medication during pregnancy and
lactation have continued to rise in North America over the past decade (1;8;9), and
antidepressant use in pregnancy is now estimated to be at least 1 in 10 women (9). The decision
to use antidepressant medication during pregnancy or lactation must be weighed against the
risks of untreated maternal depression and this risk/benefit ratio must be carefully discussed
with each patient.
Avoiding antidepressant use during pregnancy or lactation is often not an option. Studies have
shown that terminating antidepressant treatment in pregnancy in women with a previous history
of depression leads to relapse of symptoms in as much as 60-70% of women (2;3). Relapse
then exposes the developing infant to the effects of untreated depression, which has potentially
devastating consequences for the patient, infant, and family (10;11). Antenatal depression has
been associated with low maternal weight gain, increased rates of preterm birth (12), low birth
weight, increased rates of cigarette, alcohol and other substance use (13), increased
ambivalence about the pregnancy and overall worse health status (14). Additionally, prenatal
exposure to maternal stress has been shown to have consequences for the development of infant
temperament (15). Children exposed to perinatal (either during pregnancy or postpartum)
maternal depression have higher cortisol levels than infants of mothers who were not depressed
(16-19) and this finding continues through adolescence (19). Importantly, maternal treatment
of depression during pregnancy appears to help normalize infant cortisol levels (20). These
findings may partially explain the mechanism for an increased vulnerability to
psychopathology in children of mothers with antenatal depression (21).
Untreated depression during pregnancy is also one of the strongest risk factors for the
development of postpartum depression (PPD). One should note that PPD has potentially
devastating consequences including suicide and infanticide. While the risk for suicide deaths
and attempts is lower during and after pregnancy than in the general population of women,
suicides account for up to 20% of all postpartum deaths and represent one of the leading causes
of peripartum mortality (22). PPD has been associated with significantly increased rates of
infantile colic and impaired maternal-infant bonding (23). PPD is also associated with worse
parenting behavior, such as decreased rates of both infant safety and healthy child development
practices (24), and increased use of harsh discipline practices (25).
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While every case should be considered individually, many pregnant women with either a
history of MDD or new onset MDD during pregnancy require the use of antidepressants in
order to stay psychiatrically well. Since adverse outcomes for the child exposed in utero to
MDD have been demonstrated, it is important to consider MDD in the mother during pregnancy
an exposure for the baby. Keeping the mother psychiatrically well should be the overarching
goal of treatment during pregnancy for both the mother and the child. Thus, the discontinuation
of antidepressants in a pregnant or soon-to-be pregnant woman should only be done in
collaboration with the patient's psychiatrist, and after a careful review of the risk/benefit ratio
for both mother and baby has been assessed.
Lack of Data Regarding the Use of Antidepressants during Pregnancy
Unfortunately, there is limited evidence from research studies to guide the clinician treating
women with perinatal depression. Consequently, for many women, the decision making
process to either initiate or continue to use psychotropic medications during pregnancy or
lactation becomes highly stressful and emotionally painful. The woman often faces
misconceptions and incorrect information from well-intentioned family, friends and care
providers (26). Thus, although having a baby is supposed to be a time of great joy in a woman's
life, suffering from mental illness during pregnancy or postpartum can quickly become a
nightmare.
Multiple barriers exist that have compromised the accumulation of reliable data on the use of
antidepressants during the perinatal time. These barriers include ethical challenges, such as the
inability to randomly assign depressed pregnant women in clinical trials, practical challenges,
such as multiple confounding variables in observational cohort studies, as well as the lack of
an adequate comparison group in most studies which makes it difficult to determine the role
of underlying depressive illness versus antidepressant use on fetal outcomes (27;28). Thus, the
evidence base regarding the safety of antidepressant medication during pregnancy and lactation
has many holes and unanswered questions such as:
• What are the short and long term risks to the fetus of antidepressant exposure during
pregnancy?
• What is the risk to the fetus of untreated maternal depression during pregnancy?
• What are the risks of either antidepressant exposure or untreated depression to
neonates during lactation?
Despite these unanswered questions and lack of data, the clinician must help his or her patient
make appropriate clinical choices regarding antidepressant use during pregnancy, weighing
both the potential risks of untreated depression as well at the potential risks of antidepressant
use. What information is currently available to help guide physicians advice to their pregnant
patients?
FDA Guidelines
Since 1979, the Federal Drug Administration (FDA) has required that pharmaceutical product
information include information about safety during pregnancy (29). In addition, products are
classified under one of five letter categories (Table 1). Until recently, this information has been
based largely upon animal studies. Indeed, the well-known FDA pregnancy category system
(Table 1) uses evidence from animal studies as part of the definitions of 3 out of the 5 categories.
However, the categories are confusing and imply an increasing level of risk from category A
to category X which is not, in fact, the case. For example, oral contraceptives are in category
X simply because there is no reason to use them in pregnancy, not because there is evidence
of birth defects if they are used during pregnancy. Further, the level of investigation used to
Payne and Meltzer-Brody Page 3













categorize individual medications varies from medication to medication as does the level of
risk actually imposed by a particular drug. Medications may be placed in the same category
and have vastly different levels of risk and/or different levels of evidence supporting their
categorization (see Table 1). The FDA Pregnancy Categories therefore can provide a “quick
and dirty” assessment but may not provide information that is useful in planning clinical care.
In 1997 the FDA Pregnancy Labeling Task Force was formed to revise the pregnancy category
system with the goal of improving the ability of the FDA system to help clinicians make
informed clinical decisions when prescribing medications to pregnant women. (30). This Task
Force has investigated the following issues:1) the FDA categories do not address dosing; 2)
lack of consideration of time of exposure to the medication; and 3) excessive reliance on animal
data and lack of human data. In March of 2000 a FDA subcommittee proposed a new model
for pharmaceutical labeling which in May 2008 became a FDA “Proposed Rule,” meaning that
the new model is currently being considered and comments on the rule have been solicited. It
is likely that the model will become effective on or about June 30, 2010. This new model
eliminates the previously established categories and instead will provide information and
summary data on both clinical considerations and risk assessment for fertility, pregnancy and
lactation (30). This system attempts to include all currently available information in order to
help the clinician weigh the risks and benefits of prescribing a drug during pregnancy. While
providing more information to the clinician than the Category system, this approach can also
be confusing to the clinician making a risk-benefit analysis who does not have much experience
with a particular drug.
FDA “Black Box” Warnings and Public Health Advisors for Antidepressants
and Pregnancy
“Black Box” warnings are generally placed on the label of a medication when the FDA judges
that a potential side effect or complication is serious enough to warrant drawing the clinician's
attention to it immediately. A Public Health Advisory is a statement issued by the FDA
concerning a particular issue with an individual or class of medications (or food) that
summarizes all currently available information on the topic. Public Health Advisories are
generally issued when there is concerning information, but does not necessarily give specific
recommendations.
To date there is one “Black Box” warning regarding the use of a particular class of
antidepressants, serotonin reuptake inhibitors (SSRI's) and their possible association with an
increased risk for Persistent Pulmonary Hypertension (PPHN). We will review the literature
on risks associated with the SSRI's and other antidepressant medications below. In addition,
the FDA has also issued a Public Health Advisory entitled, “Treatment Challenges of
Depression in Pregnancy and the Possibility of Persistent Pulmonary Hypertension in
Newborns,” which includes information on the potential risk of relapse when women
discontinue their antidepressants for pregnancy and, in addition, summarizes the available data
known regarding not only PPHN but the risk of withdrawal symptoms in the newborn exposed
to antidepressants in utero.
Potential Risks to the Fetus Associated with Antidepressant Use During
Pregnancy
Persistent Pulmonary Hypertension
PPHN is a failure of the pulmonary vasculature to decrease resistance at birth. This results in
significant breathing difficulties for the infant, hypoxia, and usually leads to intubation. It has
about a 10-20% mortality rate and also results in significant morbidity (31). It is a very rare
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condition, affecting 1-2 infants out of 1000 in the general population (32;33). PPHN has been
associated with a number of factors including, maternal smoking (34), maternal diabetes,
sepsis, meconium aspiration, and C-section, among others (33).
To date there have been three relatively large studies on the association between SSRI's and
Persistent Pulmonary Hypertension (PPHN) in the newborn with conflicting results. The first
was published in 2006 (35) and is the basis for the FDA Alert issued in July 2006 regarding
the possible association of PPHN with SSRI antidepressants. This case-control study compared
377 women who had infants diagnosed with PPHN to 836 matched control women with infants
not diagnosed with PPHN. 14 of the infants with PPHN had been exposed to an SSRI after the
20th week of gestation compared to 6 infants who did not have PPHN (35). This generated an
adjusted (for maternal diabetes, race, body-mass index) odds ratio of 6.1. A second study, was
conducted through the Swedish Medical Birth Register for the years 1997-2005 and examined
831,324 women who had given birth during this time (36). Antidepressant use was identified
at the first antenatal care visit (usually first trimester) and through prescriptions written by the
antenatal health service. This method did not include prescriptions written by other physicians
such as psychiatrists, and thus information on antidepressant use late in pregnancy was not
complete. Of 506 infants with PPHN, 11 had been exposed early in pregnancy to an SSRI
which generated a relative risk estimate of 2.01 (CI 1.00-3.60). When only those cases that had
a known exposure late in pregnancy and were born at or after 37 weeks were included the
relative risk rose to 3.70 (CI 1.01-9.48) (36). The most recent study used data from the HMO
Research Network Center for Education and Research on Therapeutics from 1996-2000 (37).
1104 infants exposed to SSRI's during the third trimester were compared to a matched sample
of 1104 infants not exposed to SSRI's. 5 infants, 2 from the exposed group and 3 from the
nonexposed group, were identified with PPHN. There was no difference in prevalence rates
between the two groups (37).
One issue that complicates interpretation of these studies is that several factors that are
associated with the development of PPHN in the general population, including maternal
smoking, maternal diabetes, and high pre-pregnancy BMI are also associated with MDD and
psychiatric disorders in general. Future, prospective studies that control for such factors are
needed in order to fully elucidate the association between SSRI's and the development of PPHN
in the newborn. It is also important to keep the potential elevated risk in perspective by
considering the absolute risk. PPHN is an extremely rare condition, occurring in 1-2 infants
out of 1000 in the general population (32;33). If one assumes that SSRI's increase the odds of
the development of PPHN 6 times the rate in the general population, only 6-12 (0.6-1.2%)
infants exposed to SSRI's will develop PPHN out of 1000 exposed. Thus, approximately 99%
of women who take SSRI's during pregnancy will give birth to a healthy infant who does not
develop PPHN. In contrast, the risks associated with untreated depression during pregnancy
are much higher and more common.
Withdrawal Symptoms
The first report of withdrawal symptoms in babies exposed to antidepressants occurred in 1973
(38). It is unclear if “neonatal withdrawal syndrome” is actually a result of withdrawal from
the antidepressant medication or is due to a toxicity mechanism. Thus, an alternative term such
as “poor neonatal adaptation”, or “neonatal neurobehavioral syndrome” may be a better
description. There are a number of limitations in the available literature in this area, including
inconsistent definitions, no tool available to evaluate for the presence or absence of the
syndrome (for instance if an exposed infant has only constant crying does that meet the criteria
for the syndrome?), a lack of blinded ratings and a lack of studies regarding possible treatment
or prevention of the syndrome. Regardless, the FDA instituted a class labeling change in 2004
for both SSRI and SNRI (serotonin-norepinephrine reuptake inhibitors) antidepressants
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warning that third trimester exposure to antidepressants may be associated with signs and
symptoms consistent with the syndrome. According to the label change, “reported clinical
findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability,
feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor,
jitteriness, irritability, and constant crying.” The subsequent result has been that many
practitioners have recommended tapering antidepressants prior to labor and delivery even
though it remains unclear if this decreases the risk for the syndrome and if this practice increases
the risk for PPD. Furthermore, most cases of the neonatal syndrome appear to be very mild,
self-limited and do not appear to be associated with lasting repercussions (39). Additionally,
other confounding factors and unanswered questions further complicate the picture including:
1) what effect breastfeeding may have on the risk for the syndrome, and 2) minimal
characterization of maternal psychiatric illness and 3) use of multiple psychotropic agents
during pregnancy. (39). For example, available data suggests that approximately 1/3 of exposed
infants will have at least mild symptoms consistent with the syndrome and that this risk
increases when multiple agents, particularly benzodiazepines, are used (40). Clearly, larger,
more rigorous studies of the syndrome as well as strategies to minimize the rate of the syndrome
are needed. However, at this time there is simply not enough evidence from a safety perspective
to recommend tapering of antidepressants in the third trimester, particularly in cases of
moderate to severe maternal mental illness.
Antidepressants and Pregnancy: Specific Agents
Table 2 describes the currently available data on the use of specific antidepressant medications
during pregnancy and lactation. Overall, with one exception (paroxetine), there does not appear
to be an increased risk of major malformations with exposure to antidepressants in utero, though
for many agents there is little to no data available. In general, many practitioners will prescribe
SSRI medications during pregnancy since they are well-tolerated. Of the SSRI medications,
both fluoxetine and sertraline have more data regarding safety than the newer SSRI's such as
escitalopram. First trimester exposure to paroxetine has been associated with cardiac defects
and should therefore only be used if there are no other choices for that particular patient (REF).
The older tricyclic antidepressants should also be considered for use during pregnancy though
side effects, particularly constipation and orthostatic hypotension may be exacerbated by
pregnancy. There is limited data on the use of SNRI's, , bupropion, mitazapine and monoamine
oxidase inhibitors, though any of these agents may be appropriate in a particular patient.
Recommendations Regarding the Clinical Care of Women with MDD During
Pregnancy
Because of the limited evidence base, pregnant or lactating women who use antidepressant
medication often receive conflicting information regarding the safety of treatment. The
decision to use antidepressant medication in a woman with MDD during pregnancy or lactation
needs to be made on a case by case basis taking into account the following factors: 1) past
history and severity of MDD before pregnancy; 2) prior history of perinatal depression (during
pregnancy or postpartum); 3) past treatment history including both psychotropics and
psychotherapy; 4) current depressive symptoms and the degree to which they are interfering
with the patients ability to function; 5) suicidal or psychotic symptoms that should be
considered a psychiatric emergency; and finally 6) the patient's as well as the partner's (if
possible) wishes for medication use during pregnancy. Every case is different and ultimately
there are no hard and fast rules. Measurement of severity of depressive symptoms may be
quickly accomplished using a screening instrument for perinatal depression such as the
Edinburgh Scale (41), and can help the busy obstetrical provider make a rapid assessment.
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Ideally, a collaborative and multidisciplinary treatment approach that includes the patient's
psychiatrist, obstetrician, and pediatrician is critically important. This collaborative approach
provides the best opportunity to:
• Individualize treatment based on the severity and history of the mother's illness
• Appropriately educate the patient about the potential risks and benefits of treatment
versus no treatment and side effects for mother and baby
• Avoid communicating “mixed messages” to the patient about the risk and benefits of
treatment
• Institute a universal screening protocol for perinatal depression
• De-stigmatize perinatal depression
• Ensure the mental and physical health of mother and baby and family
The ideal situation is to begin planning for pregnancy prior to pregnancy. It is important to
assume that every woman of childbearing age will get pregnant and to discuss medication use
during pregnancy and use of birth control measures as part of their ongoing treatment. If a
woman is taking a medication that should clearly not be used during pregnancy a discussion
should be held with the woman and, if possible, her partner to discuss this fact and to plan what
should be done in event of accidental pregnancy. As many as 50% of pregnancies are unplanned
in the U.S. (42); this fact highlights the importance of assuming that all women of reproductive
age may become pregnant, and developing appropriate treatment and contingency plans aimed
at minimizing the chance that necessary psychiatric medications will be abruptly discontinued
and the patient will relapse.
The patient's past psychiatric history, severity of symptoms and medication response history
all play a significant role in designing a course of clinical care during pregnancy. For example,
while Prozac and Zoloft are often considered appropriate antidepressant choices during
pregnancy, if a woman has a history of not responding to either of these medications they
cannot be part of the treatment plan. Severity of illness is important to take into account: a case
in which the symptoms of depression were mild, responded well to medication and had not
recurred could be considered for discontinuation of the medication prior to pregnancy. In
contrast, a case in which depression was severe, dangerous and required hospitalization several
times would not be a candidate for medication discontinuation.
At the same time, the patient and her partner's wishes regarding medication use during
pregnancy should be taken into account when designing a treatment plan. If one or the other
is strongly against medication use during pregnancy it is best for the treatment provider to make
sure they understand the risks of no treatment to both the mother and the baby, the rates of
relapse, and to outline a course of close follow-up during and after pregnancy rather than insist
on the use of medication during pregnancy. A partnership with good communication with the
patient and her partner, as well as the treating psychiatrist, is important to maintain so that if
there is a relapse of illness the patient will remain safe and is more likely to seek care and
treatment.
While each case is individual and there are no hard and fast rules there ARE some “rules of
thumb” that can be used when designing a treatment strategy (See Table 3):
1. All medication changes should be done prior to pregnancy if possible. This minimizes
the number of exposures to the baby and promotes mood stability for the mother.
2. Ideally the patient should be stable psychiatrically for at least 3 months before
attempting pregnancy. This is not always practical but should provide some evidence
and reassurance that the patient's mood is stable prior to entering pregnancy.
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3. Use medications that we know something about: Older is usually better. If a
medication has been available for awhile there is at least some evidence that it is
unlikely to be associated with major organ malformations. See Table 2 for a
description of what is currently known about various antidepressants.
4. Minimize the number of exposures for the baby. Try to minimize the number of
medications used but also consider exposure to psychiatric illness an exposure.
Changing medications for breastfeeding increases the number of exposures. One
common scenario is for a woman on a newer antidepressant to become pregnant and
then to receive the recommendation to switch antidepressants to an older medication
that has more evidence for safety during pregnancy. While this might have made sense
prior to pregnancy, this plan would actually increase the exposures for the baby. First
the baby has already been exposed to the newer antidepressant and switching to a
second medication would be another exposure. In addition, the likelihood that the
patient would relapse while switching is high, thus exposure to the mood disorder
would be a third exposure for the child.
5. Consider breastfeeding when planning for pregnancy. Consider whether the
medication should be used during breastfeeding and what the plan would be for
monitoring the medication during breastfeeding.
6. If a baby was exposed to a medication during pregnancy, it may not make sense to
discontinue the medication (or alternatively not breastfeed) for breastfeeding. The
baby experienced a larger concentration of the drug in utero compared to the
concentration that will be found in breastmilk. That being said there are certain
medications that might be more difficult to justify continued exposure during
breastfeeding.
Conclusions
Antidepressant use during pregnancy is often necessary in order to prevent maternal psychiatric
illness. Discontinuation of antidepressants during or shortly before pregnancy has been
associated with a high rate of relapse resulting in exposure to maternal depression for the
neonate. Such exposure is not benign and has been associated with poor outcomes for both the
baby as well as the mother and may, in fact, have long-term consequences. Individualized
recommendations based on the patient's past history and medication regimen should ideally be
implemented prior to pregnancy with a goal of minimizing exposures for the baby, including
to maternal psychiatric illness. Future research in the area of perinatal psychiatry will hopefully
address many of the gaps in the literature including, for example, the safety of antidepressant
use during pregnancy and lactation, long-term outcomes for exposed children, consequences
of exposure to maternal illness, and whether antidepressants should be tapered prior to delivery.
While knowledge gaps exist and the data is limited in scope, the overall safety of antidepressant
use during pregnancy currently appears to be good with only one antidepressant associated
with major malformations. The association of SSRI antidepressants with an increased risk of
persistent pulmonary hypertension has been demonstrated in two studies, though a recent third
did not support the association. Despite the possible association, the absolute risk remains small
with less than 1% of exposed infants developing the syndrome. Neonatal withdrawal syndrome
remains an active area of controversy though interpretation of the literature is compromised
by the lack of a specific definition of the syndrome, specific measurement tools, controls for
severity of maternal illness, and blinded studies. In all cases, utilizing strategies such as
planning for pregnancy, educating the mother and family regarding the risks and benefits of
treatment as well as the potential risks of no treatment, and using a team approach will optimize
outcomes for both mother and child.
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Table 1
FDA Pregnancy Categories
FDA Category Description Problems
A Adequate, well-controlled studies in pregnant women have not shown an increased risk of fetal abnormalities.
B Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled
studies in pregnant women.
or
Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have
failed to demonstrate a risk to the fetus.
Not all drugs in this






of one small sample of
women. It has since
been reclassified at
Category C based on
animal studies.
C Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant
women.
or
No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.
Not all drugs in this
category have the same
level of risk. For
example, simethicone
which is not absorbed
systemically and
therefore is no risk to
the fetus and
carbamazapine which
is known teratogen are
both in this category
(Frederiksen)
D Studies, adequate well-controlled or observational, in pregnant women have demonstrated a risk to the fetus.
However, the benefits of therapy may outweigh the potential risk.
X Studies, adequate well-controlled or observational, in animals or pregnant women have demonstrated positive
evidence of fetal abnormalities. The use of the product is contraindicated in women who are or may become pregnant.
Some drugs are placed
in this category
because there is no
reason to use them
during pregnancy, not
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Table 2
Summary of Antidepressant Medications During Pregnancy and Lactation
Medication Dosing Range Potential adverse event(s): Pregnancy Potential adverse event(s): Lactation
Selective serotonin reuptake inhibitors
Sertraline 25mg-200mg No confirmed evidence of birth defects in 1st trimester exposure. Risk of
SSRI withdrawal syndrome with 3rd trimester exposure. (43)
Minimal detection of drug in infants serum. (44;
45)
Paroxetine 10mg-50 mg Small absolute increased risk of cardiac defects in 1st trimester exposure
(no more than 2 per 1000 births). Risk of SSRI withdrawal syndrome with
3rd trimester exposure.(43)
Minimal detection of drug in infants serum. (44;
45)
Citalopram 10mg-60 mg No confirmed evidence of birth defects in 1st trimester exposure. Risk of
SSRI withdrawal syndrome with 3rd trimester exposure.(43)
high milk/plasma concentration at higher doses.
(45)
Fluoxetine 10mg-60mg No confirmed evidence of birth defects in 1st trimester exposure. Risk of
SSRI withdrawal syndrome with 3rd trimester exposure. (43)
Long half-life can increase the potential for
accumulation. (45)
Escitalopram 10mg-20mg No confirmed evidence of birth defects in 1st trimester exposure. Risk of
SSRI withdrawal syndrome with 3rd trimester exposure.(43)
Very limited data to date shows lower milk/
plasma concentrations as compared to citalopram.
(46)
Tricyclics
Desipramine 25mg-200mg No confirmed evidence of birth defects in 1st trimester exposure. Risk of
SSRI withdrawal syndrome with 3rd trimester exposure.(43)
Minimal detection of drug in infants serum. (44;
47)
Imipramine 25mg-200mg No confirmed evidence of birth defects in 1st trimester exposure. Risk of
SSRI withdrawal syndrome with 3rd trimester exposure.(43)
Minimal detection of drug in infants serum. (44;
47)
Nortriptyline 25mg-150mg No confirmed evidence of birth defects in 1st trimester exposure. Risk of
SSRI withdrawal syndrome with 3rd trimester exposure.(43)
Minimal detection of drug in infants serum. (44;
47)
Other Antidepressants (SNRI's and others)
Mirtazepine 7.5mg-45mg Limited data available; no confirmed evidence of birth defects in 1st
trimester exposure.(43)
Limited data available. Well tolerated in small
study. Always monitor for changes in sleep and
eating behaviors. (48)
Buproprion 75g-300mg Limited data available; no confirmed evidence of birth defects in 1st
trimester exposure.(43)
Limited data available. Small increased risk of
infant seizure (case report). (49)
Venlafaxine 37.5-225mg Limited data available; no confirmed evidence of birth defects in 1st
trimester exposure.(43)
Inadequate data available
Duloxetine 20-90mg Inadequate data available.(43) Inadequate data available
MAOI's
phenelzine 15-75mg Very limited data available; no confirmed evidence of birth defects with
1st trimester exposure. (50)
Inadequate data available
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Table 3
Clinical Guidelines for Treatment of Depression During Pregnancy
Clinical Pearls
• Assume all reproductive age women will get pregnant and plan ahead
• All medication changes should be done prior to pregnancy if possible
• Ideally the patient should be stable psychiatrically for at least 3 months before attempting pregnancy
• Limit the number of exposures for the baby; Consider active depression in the mother an exposure
• Use medications that we know more about:- older generally means better
• Consider breastfeeding when planning for pregnancy
• If a baby was exposed to a medication during pregnancy, it may not make sense to discontinue the medication (or alternatively not breastfeed) for breastfeeding
• Every case is unique- there are no rules
• Use a team approach
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